Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

Affiliations

• ¹ Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. maximilian.merz@med.uni-heidelberg.de.
• ² Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. maximilian.merz@med.uni-heidelberg.de.
• ³ Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ⁴ Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
• ⁵ Institute of Human Genetics, University Heidelberg, Heidelberg, Germany.
• ⁶ Coordination Center for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany.
• ⁷ National Center for Tumor Diseases (NCT), Heidelberg, Germany.
• ⁸ Max-Eder Research Group Experimental therapies for hematologic malignancies, DKFZ, Heidelberg, Germany.
• ⁹ Asklepios Klinik und St. Georg, Altona, Hamburg, Germany.
• ¹⁰ Department of Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany.
• ¹¹ Department of Hematology and Oncology, Kath. Krankenhaus Hagen gem. GmbH - St.-Marien-Hospital, Hagen, Germany.
• ¹² Department of Hematology and Oncology, University Hospital of Essen, Essen, Germany.
• ¹³ Department of Internal Medicine I, University of Cologne, Cologne, Germany.
• ¹⁴ Department of Internal Medicine III, Klinikum Chemnitz gGmbH, Chemnitz, Germany.
• ¹⁵ II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany.
• ¹⁶ Department of Radiology, University Hospital Heidelberg, Heidelberg, Germany.
• ¹⁷ Department of Radiology, German Cancer Research Center DKFZ, Heidelberg, Germany.
• ¹⁸ Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.